OccuLogix, Inc. dba TearLab Corp.(NASDAQ:TEAR)(TSX:TLB) CEO Interview

OccuLogix, Inc. dba TearLab Corporation
Eric Donsky

This interview has expired.
Click here to find stocks, with exciting stories, and management committed to maximizing shareholder value.

Special deals for our readers
Are you qualified for the Visa Black Card?
The World’s Most Prestigious and Versatile Credit Card. Apply Now!

Be a more profitable investor:
What’s Jim Cramer trading in his personal portfolio? Click here

Get an Equifax 3-in-1 Credit Report Now!

Why are you still paying too much with Schwab, and and E-trade?? Step up to the #1 discount broker: TradeKing.
Find out why TradeKing.com was ranked #1 Discount Broker by SmartMoney Magazine two years running! (August 2006 & 2007).

Invest Smarter! Get 4 Bonus Weeks of Investor’s Business Daily Digital Edition!

LifeLock is the only Identity Theft Prevention Solution backed by a one-million dollar guarantee!Click here to get a 10% discount.

Get FICO Score Watch Now!

Free Quicken Online automatically categorizes your expenses.

Click here to get access to powerful investing tools only available at Investor’s Business Daily.

Get a free look at Jim Cramer’s Action Alerts PLUS portfolio. Click here

Corporate Info
OccuLogix, Inc. is an ophthalmic therapeutic company founded to commercialize treatments for age-related eye diseases. The Company’s product for dry AMD, the RHEO System, is designed to improve microcirculation in the eye by filtering high molecular weight proteins and other macromolecules from the patient’s plasma. The RHEO System is used to perform the Rheopheresis procedure, which the Company refers to under its trade name RHEO Therapy. The Rheopheresis procedure is a blood filtration process that selectively removes molecules from plasma. The RHEO System consists of the OctoNova Pump and a disposable treatment set, containing two filters, through which the patient’s blood circulates. On December 20, 2007, the Company sold Solx, Inc. (SOLX) to Solx Acquisition, Inc.

Did you enjoy this article? Join our FREE Newsletter!
I agree to have my personal information transfered to MailChimp ( more information )
Join over 100,000 investors and business leaders worldwide. Get the latest actionable business and investing intelligence before the rest of the crowd.
We hate spam. Your email address will not be sold or shared with anyone else.